December 8, 2016: Here are four stocks trading with relatively heavy volume among 34 equities making new 52-week lows in Thursday’s session. On the NYSE, advancers led decliners by about 3 to 2 and on ...

BMO's M. Ian Somaiya and team contend that while Gilead Sciences' (GILD) hepatitis-c sales will remain under pressure, its HIV business should make up for it: We sat down with Gilead management during ...

Gilead Sciences, Inc. today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational, once-daily single tablet regimen containing sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg for the treatment of direct-acting antiviral -experienced chronic hepatitis C virus -infected patients.